NCT03161678View on ClinicalTrials.gov

CES1 Crossover Trial of Clopidogrel and Ticagrelor

PHASE4CompletedINTERVENTIONAL
Enrollment

111

Participants

Timeline

Start Date

August 22, 2017

Primary Completion Date

December 12, 2022

Study Completion Date

December 12, 2022

Conditions
Myocardial InfarctionThrombosisPlatelet Dysfunction
Interventions
DRUG

Clopidogrel

Clopidogrel (75 mg/d for 8 days) will be administered. Measures of pharmacodynamics will be assessed pre- and post-drug administration.

DRUG

Ticagrelor

Ticagrelor (90 mg twice daily for 8 days) will be administered. Measures of pharmacodynamics will be assessed pre- and post-drug administration.

Trial Locations (1)

17602

Amish Research Clinic, Lancaster

All Listed Sponsors
lead

University of Maryland, Baltimore

OTHER

NCT03161678 - CES1 Crossover Trial of Clopidogrel and Ticagrelor | Biotech Hunter | Biotech Hunter